The company is developing a range of pharmaceutical products that are based on new chemical entities and are targeted on skin diseases that can be topically treated.

Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders characterized by severe damage of the gastro-intestinal tract.